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Background: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition in
childhood (5.3% to 7.1% worldwide prevalence), with substantial overall financial burden to children/adolescents,
their families, and society. The aims of this study were to describe the clinical characteristics of children and
adolescents with ADHD in Spain, estimate the associated direct/indirect costs of the disorder, and assess whether
the characteristics and financial costs differed between children/adolescents adequately responding to currently
available pharmacotherapies compared with children/adolescents for whom pharmacotherapies failed.
Methods: This was a multicenter, cross-sectional, descriptive analysis conducted in 15 health units representative of
the overall Spanish population. Data on demographic characteristics, socio-occupational status, social relationships,
clinical variables of the disease, and pharmacological and non-pharmacological treatments received were collected
in 321 children and adolescents with ADHD. Direct and indirect costs were estimated over one year from both a
health care system and a societal perspective.
Results: The estimated average cost of ADHD per year per child/adolescent was €5733 in 2012 prices; direct costs
accounted for 60.2% of the total costs (€3450). Support from a psychologist/educational psychologist represented
45.2% of direct costs and 27.2% of total costs. Pharmacotherapy accounted for 25.8% of direct costs and 15.5% of
total costs. Among indirect costs (€2283), 65.2% was due to caregiver expenses. The total annual costs were
significantly higher for children/adolescents who responded poorly to pharmacological treatment (€7654 versus
€5517; P = 0.024), the difference being mainly due to significantly higher direct costs, particularly with larger
expenses for non-pharmacological treatment (P = 0.012).
Conclusions: ADHD has a significant personal, familial, and financial impact on the Spanish health system and
society. Successful pharmacological intervention was associated with lower overall expenses in the management of
the disorder.
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Attention-deficit/hyperactivity disorder (ADHD) is a
common neurodevelopmental condition in childhood,
with an estimated worldwide prevalence in children/ado-
lescents ranging from 5.3% to 7.1%, with little variation
across countries and regions [1–3]. ADHD is character-
ized by developmentally inappropriate levels of inatten-
tion, hyperactivity, or impulsivity that have a significant
impact on different aspects of the child/adolescent’s
everyday life, including social, academic, or occupational
activities. The severity of ADHD and presence of par-
ticular symptoms is highly heterogeneous, and the Diag-
nostic and Statistical Manual of Mental Disorders Fifth
Edition (DSM-5) distinguishes clinical current presen-
tations as predominantly inattentive, predominantly
hyperactive/impulsive, or combined when symptoms
of inattention or hyperactivity/impulsivity coexist [4].
In addition to the core symptoms, children/adoles-
cents with ADHD have increased rates of comorbidi-
ties, including conduct disorder, learning disabilities,
oppositional defiant disorder, or depressive disorders,
that have further impact on the child/adolescent’s
everyday life [5].
ADHD significantly impairs psychosocial functioning
and adjustment, and children/adolescents usually have
difficulties in interpersonal relationships with peers/fam-
ily [6, 7]. Furthermore, poor academic performance is
more common in children/adolescents with ADHD than
in those without ADHD [8]. Consequently, compared with
non-ADHD children/adolescents, children/adolescents
with ADHD have low self-perception and self-esteem, and
impaired quality of life [9–11]. Children/adolescents with
ADHD have an increased risk of mortality, and school-age
children with ADHD are also more likely to require emer-
gency treatment or be admitted to hospital due to acci-
dental injuries, whereas adolescents with ADHD have
higher rates of early and more severe substance use, and
of serious delinquent behaviors than their non-ADHD
peers [12–15].
Health-economics literature has consistently shown
that the overall financial burden of ADHD to children/
adolescents, their families, and society is substantial [11,
16–18]. A study on costs of brain disorders in 30 Euro-
pean countries estimated that the direct annual costs of
ADHD in 2010 were €781 per person, representing a
total of €2546 million. These figures are lower than for
autism (total of €15,109 million) and slightly lower than
for conduct disorder (total of €3671 million) [19]. More-
over, ADHD annual health care costs per child/adoles-
cent vary substantially across European countries (from
€716 in Germany to €2134 in the Netherlands), and are
of a similar order of magnitude in the US ($621 to
$2720) [11]. However, comparisons are difficult regard-
ing other types of costs; for instance, special educationalsupport may be provided within mainstream schools in
some countries (e.g. the UK), but are completely exter-
nal in others (e.g., Spain).
Systematic reviews of the literature have shown that
the pharmacological treatment of ADHD is associated
with a substantial benefit in outcomes in the short term,
and is cost-effective compared with placebo, no treat-
ment, or behavioral therapy only [20, 21]. Analyses on
the effect of treatment on long-term outcomes are
scarce, but it has also been reported that untreated indi-
viduals experience worse outcomes overall than those
receiving any treatment [10, 22, 23]. Therefore, individ-
uals who are untreated or inappropriately treated, or
who do not respond adequately to treatment, may ex-
perience and/or contribute to a significant increase in
the short- and long-term financial burden of the disease
as a result of additional expenses that can be attributed
to the health, social, educational, and justice systems.
There are few studies on the economic impact of ADHD
in Europe to date, and those available are not directly
comparable with studies published in the US because of
putative underlying variations in treatment approaches
or public health policies [5].
The objective of this multicenter, cross-sectional study
was to estimate the associated direct and indirect costs
from both a health care system and a societal perspec-
tive over a 1-year time period in Spanish children/ado-
lescents with ADHD. In addition, we assessed whether
the characteristics and financial costs differed between
children/adolescents responding well (good responders)
versus those who responded poorly (poor responders) to
currently available pharmacotherapies.
Participants and methods
Study design
This was a multicenter, cross-sectional, descriptive study
in a sample of children/adolescents with ADHD in the
context of the Spanish research project “Plan of Action
in ADHD (PANDAH)”. A total of 321 children/adoles-
cents were recruited between 1 December 2012 and 30
April 2013 from 15 health care centers (7 privately and
8 publicly funded) representative of the overall Spanish
population.
Study population
The study included children/adolescents with DSM-IV
Text Revision (DSM-IV-TR) diagnostic criteria for
ADHD, aged ≤18 years, and without intellectual disabil-
ity (i.e. intelligence quotient ≥70), as estimated by the
treating physician. Children/adolescents were excluded if
they had one of the following conditions: a severe med-
ical disease other than asthma (e.g. neoplasm, diabetes
mellitus, Crohn’s disease), neurological disorders (e.g.
epilepsy), severe psychiatric disorders (including
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disorders), symptoms of major depression before the
onset of ADHD, or ADHD symptoms during episodes of
depression.
To minimize selection bias, child/adolescent psych-
iatry or pediatric neurology units initially recruited the
first child/adolescent who attended on a given day who
fulfilled study inclusion criteria. When additional chil-
dren/adolescents attended on the same day, only those
consecutive to the first one were enrolled.
Sample size calculation
To detect a mean cost difference of €2000 between good
responders and poor responders, and assuming a stand-
ard deviation (SD) of €5000 and €7000, respectively, we
calculated that the total sample size needed was 350
children/adolescents (α = 0.05; β = 0.2). As the study was
conducted in 15 different health care centers, each one
should recruit between 20 and 30 children/adolescents.
Ethical considerations
The central Ethics Committee that approved the study
was the Niño Jesús Hospital Committee (Madrid), and
all children/adolescents or their legal representatives
signed a written informed consent form prior to partici-
pation in the study.
Data collection
A case report form (CRF) to be completed by the inves-
tigators was specifically designed for the study. First, a
pilot study was conducted at 3 of the participating cen-
ters and data entered for 2 children/adolescents; this
served to detect possible misleading questions, or other
problems encountered by the investigators when com-
pleting the questionnaires. Second, all participating in-
vestigators were trained in the usage of the final CRF
through a conference call. The CRFs were collected each
week from all participating centers to build a common
database.
Study variables
At the time of recruitment, the following data were col-
lected and recorded by the investigators during the
interview: a) current demographic characteristics of chil-
dren/adolescents; b) socio-occupational status; c) social
relationships; d) date of diagnosis, ADHD subtype, and
psychiatric comorbidities based on DSM-IV-TR criteria
[24]; e) ADHD symptom severity for the last 6 months
(baseline or current severity) using ADHD rating scale-
IV (ADHD-RS-IV) [25]; f ) severity of the disease at the
time of recruitment evaluated using the Clinical Global
Impression questionnaire [26]; g) general current func-
tioning of the child/adolescent using the Children’s Glo-
bal Assessment Scale (CGAS) [27]; h) the lowest knownCGAS score during the previous year; and i) pharmaco-
logical and non-pharmacological ADHD-related treat-
ments received in the previous 12 months. Available
drugs for ADHD treatment in Spain at the time of the
study included methylphenidate (MPH) OROS, MPH
pellets, MPH immediate release (IR), and atomoxetine.
Finally, the parents/caregivers were asked to provide
data on utilization of health care services by the child/
adolescent for the prior 12 months and their own work
productivity, assessed using the Work Productivity and
Activity Impairment questionnaire [28].
Data analyses and statistics
Descriptive analysis
Descriptive analyses were summarized by means (SDs)
or medians and interquartile ranges for continuous
variables, and absolute numbers and percentages for
categorical variables.
Cost analysis
The study was performed using a health care system and
a societal perspective to estimate both direct and indir-
ect costs, and adopted a 1-year time period.
All costs are expressed in 2012 Euros. Direct medical
costs were defined as the cost of resources consumed to
detect and treat the disorder, including costs of diagnos-
tic tests, blood tests, emergency/outpatient visits, hos-
pital admissions, and medication use. Direct medical
costs were estimated by multiplying the amount of con-
sumed resources by unit costs. These were obtained
from the individual official reimbursed process in each
particular region because, in Spain, health care is a com-
petence of each autonomous community. Transport to
treatment center was classified as a non-medical direct
cost, and estimated based on public transport or taxi
tickets given to the child/adolescent and parent/care-
giver. Total direct costs were the sum of medical and
non-medical costs. Indirect costs were those faced be-
cause of ADHD symptoms, and defined as the costs of
the child/adolescent’s parents or caregivers, and the cost
of lost productivity – as a consequence of hours spent in
medical visits or missing workdays due to sick leave –
applied to parents or caregivers. The cost of lost prod-
uctivity was calculated by multiplying the estimated
number of lost working hours by the average wage per
working-hour [29]. More intangible costs, such as grade
repetition, school drop-out, and time spent attending
psychologist/educational psychologist visits, were de-
scribed as proportions or means (SDs) (e.g. mean [SD]
number of visits per year).
Comparison between good responders and poor responders
Good responders were defined as children/adolescents
treated pharmacologically for at least 9 months who had
Quintero et al. BMC Psychiatry  (2018) 18:40 Page 4 of 10an ADHD-RS-IV total score ≤ 18 (i.e. never, rarely, or
sometimes ill) for at least the 3 previous months [30, 31].
Conversely, poor responders were children/adolescents
who, despite receiving pharmacological treatment for at
least 9 months, had an ADHD-RS-IV total score > 18. The
comparison between good responders and poor re-
sponders was calculated using the chi-square or Fisher’s
exact test for categorical variables. For continuous
variables, the Student’s t test was used for normally
distributed variables, and the Mann-Whitney test for non-
normally distributed variables. P-values were unadjusted
for multiplicity.
Results
Sample description and demographic characteristics
A total of 321 children/adolescents were enrolled in the
study; 262 were recruited by child/adolescent psychia-
trists, 59 by neuropediatricians. Table 1 summarizes the
clinical and demographic baseline characteristics of the
study sample. The age of the sample ranged between 6.3
and 18.0 years (mean [SD] 12.7 [2.9] years); most chil-
dren/adolescents were male (78.5%) and 16 were youn-
ger than 8 years of age. The most frequent clinical
presentation was combined ADHD type (61.4%), and the
most common comorbidities were oppositional defiant
disorder and anxiety disorders (19.9% and 17.8% of
cases, respectively). At baseline, treating physicians ratedTable 1 Clinical and demographic baseline characteristics of
the study sample (N = 321)
Characteristic Cases
Age, years, mean (SD) 12.7 (2.9)
Age, years, range (P25, P75) 6.3–18.0 (10.6, 15.1)
Sex, n (%)
Male 252 (78.5)
Female 69 (21.5)
ADHD presentation, n (%)
Combined 197 (61.4)
Predominantly inattentive 112 (34.9)
Predominantly hyperactive-impulsive 12 (3.7)
ADHD-RS-IV score, mean (SD) 22.04 (10.3)
Duration of the disorder, years, mean (SD) 3.83 (2.5)
Current level of functioning (CGAS), mean (SD) 74 (15.3)
Lowest CGAS during the previous year, mean (SD) 56.1 (15.6)
Comorbidities, n (%)
Oppositional defiant disorder 64 (19.9)
Other conduct disorders 19 (5.9)
Anxiety disorders 57 (17.8)
Addictions 6 (1.9)
ADHD attention-deficit/hyperactivity disorder; ADHD-RS-IV ADHD rating scale
IV; CGAS Children’s Global Assessment Scale; P25 25th percentile; P75 75th
percentile; SD standard deviationchildren/adolescents as being mild to moderately ill in
73.9% of cases, and most had a good level of functioning
with minor impairments (CGAS mean [SD] score = 74
[15.3]).
Most children/adolescents were currently living with
their parents and siblings (63.6%); their relationship with
their family was good in 53.0% of cases. However, be-
cause of the ADHD symptoms, 17.8% of parents had to
give up their job to care for their child/adolescent, and
11.5% of children/adolescents had a caregiver other than
their parents, of whom 54% were relatives.
Relationship with peers was good overall (59.5% of
cases), but, in 43.0% of cases, parents reported that the
child/adolescent had some type of social difficulty such
as being led by others, provoking and annoying others,
or being sore losers (e.g. becoming very upset or angry
when he or she loses a game, contest, etc).
All children/adolescents were attending school except
one who was unemployed; 51% were enrolled in partially
State-funded institutions, 35% in public schools, and
14% in private institutions. At the academic level, 19.1%
of children/adolescents required an adapted school cur-
riculum, and 51.9% received reinforcement/tutoring les-
sons about 4 times/week (mean [SD] = 4.2 [3.8]). A total
of 13.7% of children/adolescents had been expelled from
school at least once, with a mean (SD) age at first expul-
sion of 12 (2.5) years, and a mean (SD) of 3.3 (4) expul-
sions. Finally, 33.6% repeated a grade (mean [SD]
repetitions = 1.1 [0.3]), at a mean (SD) age of 10.6 (2.8)
years for the first time.
Cost analysis
The average estimated total cost of ADHD per year per
child/adolescent was €5732.64, with direct costs ac-
counting for 60.2% of total costs (€3450.04) (Table 2).
The most frequently accessed health service was a visit
to a psychiatrist, with a median of 4 visits per year (25th
percentile [P25] = 2; 75th percentile [P75] = 6), followed
by visits to a primary care center (median of 2 visits;
P25 = 0; P75 = 4). Support from an educational psycholo-
gist or a psychologist (non-pharmacological treatment)
was needed by 37.4% and 32.7% of children/adolescents,
respectively, in the majority of cases held at private cen-
ters (75.8% and 62.8%, respectively), and represented
45.2% of direct costs and 27.2% of total costs. Pharmaco-
therapy accounted for 25.8% of direct costs and 15.5% of
total costs. Stimulants, specifically MPH OROS (65.4%)
and MPH IR (25.5%) were the most commonly pre-
scribed drugs. The mean duration of treatments dur-
ing the previous year was 288 and 252 days for MPH
OROS and MPH IR, respectively (data not shown).
Costs due to hospital admissions, diagnostic tests, and
transportation to treatment centers represented 2% of
total costs each.
Table 2 Estimates of annual resource use and costs in 321 children and adolescents with ADHD
Costs Use of resource Mean cost in € (SD) Percentage of total cost
Direct medical costs Visits to health services, mean (SD); median (P25, P75) 703.40 (785.64) 12.3%
Primary care center 3.3 (5.8); 2 (0, 4)
Psychiatrist 5.02 (6.0); 4 (2, 6)
Another specialista 1.59 (3.5); 0 (0, 2)
Hospital admissions, mean (SD) 95.42 (958.49) 1.7%
Visits to emergency departments 0.3 (0.8)
Number of admissions 0.01 (0.1)
Days admitted 0.02 (0.2)
Stays in day hospital 0.54 (6.0)
Diagnostic tests, mean (SD) 98.43 (205.46) 1.7%
Hemogram 0.46 (0.8)
Clinical chemistry 0.47 (0.9)
Urinalysis 0.16 (0.7)
NMR 0.08 (0.4)
EEG 0.09 (0.3)
ECG 0.2 (0.4)
CT scan 0.01 (0.1)
Evoked potentials 0.01 (0.1)
Pharmacotherapy,b n (%) 889.77 (674.72) 15.5%
MPH OROS 210 (65.4)
MPH pellets 72 (22.4)
MPH IR 82 (25.5)
Atomoxetine 59 (18.4)
Clonidine 3 (0.9)
Other 37 (11.5)
Non-pharmacological treatment, n (%) 1561.14 (2768.53) 27.2%
Educational psychologist 120 (37.4)
Psychologist 105 (32.7)
Direct non-medical costs Transportation to treatment center,c n (%) 101.88 (182.89) 1.8%
Walking 27 (8.4)
Private car 223 (69.5)
Taxi 2 (0.6)
Public transport 68 (21.2)
Total direct costs 3450.04 (3370.92) 60.2%
Indirect costs Caregiving, hours/day, mean (SD) 4.6 (2.5) 1488.16 (5141.73) 26.0%
Caregiving, days/week, mean (SD) 4.9 (1.7)
Sick leave, days, mean (SD)d 2.55 (45.7) <1.0%
Total sick leave 8.5 (2.12)
Leave due to ADHD 5 (7.1)
Time spent at medical visitsd 791.89 (625) 13.8%
Total indirect costs 2282.60 (5391.28) 39.8%
Total costs 5732.64 (7211.39) 100%
aThis includes neuropediatricians, but not psychologists/educational psychologists; bChildren/adolescents were allowed to have more than one
pharmacological treatment; cn = 320; dApplied to parents or caregivers of children/adolescents with ADHD
ADHD attention-deficit/hyperactivity disorder; CT computerized tomography; ECG electrocardiogram; EEG electroencephalogram; IR immediate release;
P25 25th percentile; P75 75th percentile; MPH methylphenidate; NMR nuclear magnetic resonance; SD standard deviation
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caregiver expenses, which were paid by a relative in
35.1% of cases (data not shown), and represented 26% of
the total costs. Moreover, a parent or caregiver had to
leave their job to care for the child/adolescent in 17.8%
of cases, and the average number of lost working days in
the previous year was 8.5, of which 5 (SD 7.1) days were
due to ADHD itself (Fig. 1 and Table 2).
Impact of response to ADHD treatment
In the overall sample, 73.5% (n = 236) of children/ado-
lescents received pharmacological treatment, and treat-
ing physicians considered that 58.8% (n = 139) were
good responders.
There were no differences between good and poor re-
sponders with respect to type of treatment or treatment
duration, but good responders (n = 139) had less severe
ADHD measured at baseline, greater improvement from
baseline, and were less frequently diagnosed with oppos-
itional defiant disorder (Table 3 and Additional file 1:
Table S1). Moreover, in poor responders (n = 97), the
disorder had a more negative impact on several aspects
of their lives, including poorer global functioning, with
worse relationships with friends and family.
The difference in total annual costs of ADHD between
groups was statistically significant, and higher for poor
responders compared with good responders (mean [SD]:
€7654 [€8966] versus €5517 [€6618]; P = 0.024). This
was mainly due to significantly higher direct costs for
poor responders versus good responders (mean [SD]:Fig. 1 National ADHD-related costs by cost categories€4508 [€3922] versus €3258 [€2635]; P = 0.005), attribut-
able to higher expenses in non-pharmacological treat-
ment and transport (P = 0.012 and <0.0001, respectively)
(Fig. 2). Finally, there was a trend towards a greater eco-
nomic impact on indirect costs for poor responders
(P = 0.058) driven by significantly longer time spent at
visits (P = 0.011).
Discussion
In this study, we evaluated the economic impact of
ADHD on the utilization of health care resources and
societal costs in Europe as well as the costs of this neu-
rodevelopmental disorder in children/adolescents from
the societal perspective. In addition, we assessed how
these costs differed between children/adolescents who
adequately responded to pharmacological treatment
compared with those for whom treatment response was
poor.
Although few studies have assessed the economic im-
pact of ADHD on the utilization of health care resources
and societal costs in Europe, estimates of costs vary be-
tween studies depending on types of services included
and methodology. The annual health care costs per
child/adolescent with ADHD in Europe (adjusted to
2012 Euros) have been estimated to be between €716
and €3888 [11, 32]. The results of this study are in line
with these estimates, with direct medical costs in Spain
of €3450.04, accounting for 60.2% of all expenditures.
However, it is largely recognized that, unlike many med-
ical diseases, a significant proportion of the financial
Table 3 Significant differences between children/adolescents with good response versus those with poor response to
pharmacological treatment
Good responders
(n = 139)
Poor responders
(n = 97)
P-value
Characteristics of the disease, mean (SD)
Current level of functioning (CGAS) 78.6 (12.9) 67.9 (16.3) <0.0001
Lowest CGAS score during the previous year 58.5 (14.2) 67.9 (16.3) 0.001
Current severity, n (%)
Moderately-severely ill 36 (25.9) 63 (64.9) <0.0001
Comorbidities, n (%)
Oppositional defiant disorder 20 (14.4) 27 (27.8) 0.01
Other conduct disorders 7 (5.0) 8 (8.2) 0.40
Anxiety 21 (15.1) 24 (24.7) 0.07
Addictions 1 (0.7) 4 (4.1) 0.16
Impact on social functioning, n (%)
Bad relationship with friends 1 (0.7) 15 (16.7)a <0.0001
Bad relationship with family 7 (5.0) 22 (22.7) <0.0001
an = 90
CGAS Children’s Global Assessment Scale, SD standard deviation
Fig. 2 ADHD costs (€) in children/adolescents with adequate pharmacological treatment response versus those for whom treatment failed
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costs [33]. The few available studies conducted in the
European Union that estimated indirect costs of ADHD
found values varying between €50 and €5596 per year, a
difference that may be largely explained by the type of
services considered [11, 34–36]. In the current study,
indirect costs amounted to €2282.60, and were driven
mainly by payment to a caregiver.
The main contributor to direct costs corresponded to
non-pharmacological interventions (e.g. intervention by
an educational psychologist or clinical psychologist), and
accounted for 45.2% of total direct costs and 27.2% of
total costs. Most cost-of-illness studies in ADHD include
these services together with costs of other health care
professionals, and therefore the specific weight of costs
due to psychological interventions is difficult to com-
pare. Nonetheless, these results are similar to a German
study that considered the costs of behavioral therapy
separately from other types of interventions, and re-
ported that this expenditure represented 46.6% of costs
for children/adolescents aged 6–17 years, and up to
74.4% in children ≤5 years of age [32]. Moreover, we did
not consider special education needs, which might have
contributed to an underestimation of the total costs in
our study. Available European studies (conducted in the
UK) that considered the costs of educational needs, such
as special school, support teacher, or adapted school cur-
riculum, reported them to be about 3-fold the sum of all
other costs [36], or 44% of the total costs [18], and they
were estimated to account for 30–40% of all expendi-
tures in the US [16]. Although not directly comparable,
our results seem to be in line with these estimates of the
high burden due to special educational needs in chil-
dren/adolescents with ADHD. The average proportion
of costs of medication in the present study was 15.5%,
which is in line with previous European studies that esti-
mated that they range between 12% and 28.2% [32, 37–39].
One striking finding of our study was the high cost as-
sociated with the employment of a caregiver, which rep-
resented 65.2% of indirect costs, and 26% of all costs.
Mental health-related problems in caregivers and fam-
ilies of children/adolescents with ADHD include stress,
anxiety, and depression [40], but the financial burden on
caregivers has not been routinely explored [1]. In our
study, a parent had to leave their job to care for the
child/adolescent in 17.8% of cases, thus hiding a signifi-
cant unquantified productivity loss. Moreover, this
shows that the costs we estimated to caregiving, al-
though high, are largely an underestimation of the actual
economic impact on families and society as a whole.
In this study, poor responders were observed to have
worse global functioning, and poorer relationships with
friends and family. This is in line with the results of sev-
eral systematic reviews, which reported that treatmenthas a beneficial effect on multiple short- and long-term
outcomes, including self-esteem, social functioning, aca-
demic performance, and antisocial behavior, among
others, when compared with children/adolescents with-
out ADHD or those with untreated ADHD [10, 22, 23].
Our results, however, also show that beyond symptom
control, a poor response to treatment is an important
component in the global negative impact of ADHD. This
stresses the need for individualized treatment plans to
optimize child/adolescent’s outcomes, such as the in-
corporation of patient-oriented factors (e.g. age, ADHD
subtype, comorbidities, and treatment/treatment re-
sponse history) as well as the preferences and attitudes
of children/adolescents and parents/caregivers to
pharmacotherapy [41].
Poor responders were found to incur higher total finan-
cial expenses than good responders, a difference mainly
due to direct medical costs, and particularly because of
significantly higher costs of non-pharmacological treat-
ment. Although not directly comparable, these results are
in line with previous systematic reviews showing that
treatment is associated with less use of ancillary services,
including school-, health-, and work-related services; fi-
nancial assistance services; use of the justice system; and
fewer emergency room visits [22, 23].
The main advantage of the current study is that the
studied population is representative of different regions
in Spain and data were complete for almost all variables
studied. However, the results must be interpreted in the
light of considerable limitations. First, the cross-
sectional nature of the study, with information obtained
retrospectively through interview for some variables,
means that results may be more sensitive to potential re-
call bias. Second, children/adolescents recruited in this
study were treated by psychiatrists and neuropediatri-
cians, and may therefore be representative of a subset of
children/adolescents with more severe ADHD, thus in-
curring higher costs, as for adults [42]. Third, there are
several factors that were not quantified in the study that
might have contributed to an underestimation of the
total ADHD-related costs. For example, we did not in-
clude additional indirect costs such as health-related
problems among family members, although these may
be considerable too, as suggested by a Dutch study that
estimated annual average health care costs per family
member as 14.3% of all health care costs [11, 37]. More-
over, we did not estimate costs associated with psychi-
atric/non-psychiatric comorbidities, which have been
shown to cause a 6-fold increase in medical costs com-
pared with ‘pure’ ADHD cases [37]. Although excluding
comorbidities can lead to a significant underestimation
of the total cost of illness, when it is difficult to separ-
ately assess the expenditures of closely related disorders,
it can also potentially lead to an inflation of cost
Quintero et al. BMC Psychiatry  (2018) 18:40 Page 9 of 10estimates [43]. In addition, we did not estimate ADHD-
related costs due to the justice system, treatment of
comorbid substance abuse, or traffic accidents. None of
the available European studies have quantified these
totals, but the costs of justice system service needs for
children/adolescents with ADHD in the US were esti-
mated to be about 1% of the total costs of ADHD [16].
Conclusions
ADHD is a highly prevalent disorder associated with a
significant high personal, familial, and financial impact
on the family, health system, and society. An adequate
response to pharmacological treatment was associated
with lower overall expenses in the management of the
disorder.
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